<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845934</url>
  </required_header>
  <id_info>
    <org_study_id>N/2013/65</org_study_id>
    <nct_id>NCT02845934</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis</brief_title>
  <acronym>MODIMUCOR</acronym>
  <official_title>Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study evaluates the performance (sensitivity, specificity, positive and negative&#xD;
      predictive value values and likelihood ratios) of the DNA detection test for the diagnosis of&#xD;
      mucormycosis by comparing it to the routine tests such as CT scan aspects, histopathology,&#xD;
      microscopy and fungal culture, in a test group of 52 patients including :&#xD;
&#xD;
        -  patients at high-risk according to the EORTC/MSG criteria (patients with prolonged&#xD;
           severe neutropenia, receiving corticosteroids or T-cell suppressors, recipients of&#xD;
           allogeneic HSCT, or inherited severe immunodeficiency),&#xD;
&#xD;
        -  patients with other predisposing factors of invasive mould disease ( diabetes, AIDS,&#xD;
           haematological malignancies or solid tumours, trauma, burns); Patients already diagnosed&#xD;
           with probable or proven mucormycosis irrespective of underlying conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients eligible for this study will already be hospitalized with repeated monitoring of&#xD;
      clinical and biological parameters.&#xD;
&#xD;
      Participation in the study will result in an additional sampling of blood (estimated volume 6&#xD;
      mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a&#xD;
      maximum of 8 weeks.&#xD;
&#xD;
      vials will be added to the routine sampling of these patients (ie, at the time of routine&#xD;
      sampling for galactomannan antigemia), and no new sampling procedure will be required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>test performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>sensitivity, specificity, positive and negative predictive values and likelihood ratios of the DNA serum detection test will be calculated in probable and proven mucormycosis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Mucormycosis</condition>
  <arm_group>
    <arm_group_label>Mucormycosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.</description>
    <arm_group_label>Mucormycosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspicion of invasive mould infection&#xD;
&#xD;
               -  in a patient at high risk according to the EORTC/MSG criteria updated in 2008&#xD;
                  (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell&#xD;
                  suppressor, recipients of allogeneic HSCT, or inherited severe immunodeficiency)&#xD;
&#xD;
               -  or in a patient with other predisposing factors of invasive mould disease (&#xD;
                  diabetes, AIDS, haematological malignancies or solid tumours, trauma, burns).&#xD;
&#xD;
          -  Patients already diagnosed with probable or proven mucormycosis irrespective of&#xD;
             underlying conditions, including patients referred from other centers.&#xD;
&#xD;
          -  Only adult patients (18 years or older) will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age : under 18 years&#xD;
&#xD;
          -  Patients previously included in the trial with a diagnosis of mucormycosis. However&#xD;
             patients previously entered in the trial with a diagnosis other than mucormycosis will&#xD;
             be eligible for re- new inclusion.&#xD;
&#xD;
          -  Presence of any medical condition that would not allow collection of blood samples for&#xD;
             the qPCR test.&#xD;
&#xD;
          -  History of documented, successfully treated, prior mucormycosis.&#xD;
&#xD;
          -  protected people (pregnant women, minor, guardianship…)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP_Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP_ Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP_St-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucormycosis</mesh_term>
    <mesh_term>Zygomycosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

